Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study

Background: Metformin had been recommended as the first-line treatment for type 2 diabetes since 2006 because of its low cost, high efficacy, and potential to reduce cardiovascular events, and thus death. However, dipeptidyl peptidase-4 (DPP-4) inhibitors are the most commonly prescribed first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Yoshihiro, Yoshizawa, Shunsuke, Tachi, Tomoya, Teramachi, Hitomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456525/
https://www.ncbi.nlm.nih.gov/pubmed/36078917
http://dx.doi.org/10.3390/jcm11174988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456525/
https://www.ncbi.nlm.nih.gov/pubmed/36078917
http://dx.doi.org/10.3390/jcm11174988

Ejemplares similares